Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -84K | -82K | -1M | -869K | -638K |
| Operating Income | -25M | -18M | -41M | -77M | -30M |
| EBITDA | -1M | -20M | -39M | -77M | -32M |
| Net Income | -5M | -20M | -39M | -68M | -30M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.02
+100.00% today
1Y Change
-96.43%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Windtree Therapeutics, Inc. (WINT) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 96.4% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +97.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +97.8%, free cash flow -14.6% with operating margin -37218.9% and ROIC -454.9%. Valuation already assumes a fairly strong business story at price/sales 8.2. Stock Foundry combines WINT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WINT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WINT Max Drawdown
-99.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WINT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$30.3M
+55.2% YoY
Free Cash Flow
-$25.6M
-6.9% YoY
Revenue Growth
+0.0%
EPS Growth
+97.8%
Gross Margin
12.2%
Net Margin
-44447.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -84K | -82K | -1M | -869K | -638K |
| Operating Income | -25M | -18M | -41M | -77M | -30M |
| EBITDA | -1M | -20M | -39M | -77M | -32M |
| Net Income | -5M | -20M | -39M | -68M | -30M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 4M | 6M | 22M | 17M |
| Total Assets | 28M | 32M | 38M | 75M | 113M |
| Total Liabilities | 18M | 29M | 28M | 33M | 43M |
| Shareholder Equity | 10M | 3M | 10M | 42M | 70M |
| Total Debt | 2M | 17M | 2M | 3M | 4M |
| Net Debt | 43K | 13M | -4M | -19M | -13M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
25M
-7.0% YoY
Capital Expenditures
291K
-4.3% YoY
Free Cash Flow
26M
-6.9% YoY
Key ratios
Gross Margin
12.2%
Operating Margin
-37218.9%
Net Margin
-44447.8%
ROE
-1302.8%
Debt / Equity
-1.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.